Avecho Biotechnology Limited (AVE.AX)
AUD 0.0
(-20.0%)
AUD 0.0
(-20.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.24 Million AUD | -109.46% |
| 2022 | -2.1 Million AUD | 48.92% |
| 2021 | -2.97 Million AUD | -44.59% |
| 2020 | -2.27 Million AUD | -324.34% |
| 2019 | 1.19 Million AUD | 129.9% |
| 2018 | -4.25 Million AUD | 52.84% |
| 2017 | -9.01 Million AUD | 5.73% |
| 2016 | -9.55 Million AUD | 11.87% |
| 2015 | -10.84 Million AUD | -18.91% |
| 2014 | -8.78 Million AUD | 36.12% |
| 2013 | -14.05 Million AUD | -29.21% |
| 2012 | -10.8 Million AUD | -4.21% |
| 2011 | -10.6 Million AUD | -346.92% |
| 2010 | -4.81 Million AUD | 149.99% |
| 2009 | -8.93 Million AUD | -109.1% |
| 2008 | -9.95 Million AUD | 909.01% |
| 2007 | -11.67 Million AUD | -35.82% |
| 2006 | -8.59 Million AUD | -125.95% |
| 2005 | -8.42 Million AUD | -118.92% |
| 2004 | -1.42 Million AUD | -133.56% |
| 2003 | -743.77 Thousand AUD | -262.82% |
| 2002 | -998.7 Thousand AUD | -111.81% |
| 2001 | 1.73 Million AUD | 173.94% |
| 2000 | -2.34 Million AUD | -333.13% |
| 1999 | 1 Million AUD | 113.04% |
| 1998 | -7.72 Million AUD | 83.25% |
| 1997 | -46.1 Million AUD | -585.22% |
| 1996 | -6.72 Million AUD | -117.54% |
| 1995 | 38.36 Million AUD | 3629.35% |
| 1994 | -1.08 Million AUD | -146.69% |
| 1993 | 2.32 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.09 Million AUD | 0.0% |
| 2023 Q2 | -2.41 Million AUD | 0.0% |
| 2023 FY | - AUD | -109.46% |
| 2023 Q4 | -1.99 Million AUD | 0.0% |
| 2022 Q4 | -1.87 Million AUD | 0.0% |
| 2022 Q2 | -954.06 Thousand AUD | 0.0% |
| 2022 FY | - AUD | 48.92% |
| 2021 Q2 | -1.94 Million AUD | 0.0% |
| 2021 Q4 | -2.17 Million AUD | 0.0% |
| 2021 FY | - AUD | -44.59% |
| 2020 Q4 | -1.66 Million AUD | 0.0% |
| 2020 FY | - AUD | -324.34% |
| 2020 Q2 | -1.18 Million AUD | 0.0% |
| 2019 Q2 | 2.4 Million AUD | 0.0% |
| 2019 Q4 | -1.12 Million AUD | 0.0% |
| 2019 FY | - AUD | 129.9% |
| 2018 FY | - AUD | 52.84% |
| 2018 Q2 | -2.27 Million AUD | 0.0% |
| 2018 Q4 | -1.97 Million AUD | 0.0% |
| 2017 FY | - AUD | 5.73% |
| 2017 Q2 | -4.35 Million AUD | 0.0% |
| 2016 FY | - AUD | 11.87% |
| 2016 Q4 | -4.56 Million AUD | 0.0% |
| 2016 Q2 | -4.99 Million AUD | 0.0% |
| 2015 FY | - AUD | -18.91% |
| 2015 Q4 | -6.02 Million AUD | 0.0% |
| 2015 Q2 | -4.82 Million AUD | 0.0% |
| 2014 Q4 | -5.19 Million AUD | -303.11% |
| 2014 Q1 | -1.28 Million AUD | 0.0% |
| 2014 Q2 | -3.59 Million AUD | -178.96% |
| 2014 FY | - AUD | 36.12% |
| 2014 Q3 | -1.28 Million AUD | 64.15% |
| 2013 Q3 | -2.19 Million AUD | 65.6% |
| 2013 Q4 | -1.28 Million AUD | 41.39% |
| 2013 FY | - AUD | -29.21% |
| 2013 Q1 | -2.19 Million AUD | 0.0% |
| 2013 Q2 | -6.38 Million AUD | -190.69% |
| 2012 Q2 | -1.53 Million AUD | 0.0% |
| 2012 Q1 | -1.53 Million AUD | 0.0% |
| 2012 Q4 | -2.19 Million AUD | -43.18% |
| 2012 FY | - AUD | -4.21% |
| 2012 Q3 | -1.53 Million AUD | 0.0% |
| 2011 Q4 | -1.53 Million AUD | 39.06% |
| 2011 Q3 | -2.51 Million AUD | 0.0% |
| 2011 Q2 | -2.51 Million AUD | 0.0% |
| 2011 FY | - AUD | -346.92% |
| 2011 Q1 | -2.51 Million AUD | 0.0% |
| 2010 FY | - AUD | 149.99% |
| 2010 Q3 | -3.3 Million AUD | 0.0% |
| 2010 Q4 | -2.51 Million AUD | 23.72% |
| 2010 Q1 | -3.3 Million AUD | 0.0% |
| 2010 Q2 | -3.3 Million AUD | 0.0% |
| 2009 Q2 | -2 Million AUD | 0.0% |
| 2009 Q4 | -3.3 Million AUD | -64.37% |
| 2009 Q3 | -2 Million AUD | 0.0% |
| 2009 FY | - AUD | -109.1% |
| 2009 Q1 | -2 Million AUD | 0.0% |
| 2008 Q1 | -27.78 Million AUD | 0.0% |
| 2008 Q2 | -27.78 Million AUD | 0.0% |
| 2008 Q3 | -27.78 Million AUD | 0.0% |
| 2008 Q4 | -2 Million AUD | 92.77% |
| 2008 FY | - AUD | 909.01% |
| 2007 Q2 | -2.16 Million AUD | 0.0% |
| 2007 FY | - AUD | -35.82% |
| 2007 Q1 | -2.16 Million AUD | 0.0% |
| 2007 Q3 | -2.16 Million AUD | 0.0% |
| 2007 Q4 | -27.78 Million AUD | -1184.24% |
| 2006 FY | - AUD | -125.95% |
| 2006 Q4 | -2.16 Million AUD | -45.06% |
| 2006 Q3 | -1.49 Million AUD | 0.0% |
| 2006 Q2 | -1.49 Million AUD | 0.0% |
| 2006 Q1 | -1.49 Million AUD | 0.0% |
| 2005 Q2 | -2.1 Million AUD | 0.0% |
| 2005 Q4 | -1.49 Million AUD | 29.22% |
| 2005 Q3 | -2.1 Million AUD | 0.0% |
| 2005 FY | - AUD | -118.92% |
| 2005 Q1 | -2.1 Million AUD | 0.0% |
| 2004 Q4 | -2.1 Million AUD | -33.87% |
| 2004 FY | - AUD | -133.56% |
| 2004 Q2 | -1.57 Million AUD | 0.0% |
| 2004 Q3 | -1.57 Million AUD | 0.0% |
| 2004 Q1 | -1.57 Million AUD | 0.0% |
| 2003 Q2 | -1.33 Million AUD | 0.0% |
| 2003 Q4 | -1.57 Million AUD | -18.28% |
| 2003 Q3 | -1.33 Million AUD | 0.0% |
| 2003 Q1 | -1.33 Million AUD | 0.0% |
| 2003 FY | - AUD | -262.82% |
| 2002 FY | - AUD | -111.81% |
| 2002 Q4 | -1.33 Million AUD | 38.6% |
| 2002 Q3 | -2.16 Million AUD | 0.0% |
| 2002 Q2 | -2.16 Million AUD | 0.0% |
| 2002 Q1 | -2.16 Million AUD | 0.0% |
| 2001 Q1 | -2.67 Million AUD | 0.0% |
| 2001 FY | - AUD | 173.94% |
| 2001 Q2 | -2.67 Million AUD | 0.0% |
| 2001 Q4 | -2.16 Million AUD | 18.94% |
| 2001 Q3 | -2.67 Million AUD | 0.0% |
| 2000 Q3 | -587 Thousand AUD | 0.0% |
| 2000 Q4 | -2.67 Million AUD | -355.5% |
| 2000 FY | - AUD | -333.13% |
| 2000 Q2 | -587 Thousand AUD | 0.0% |
| 2000 Q1 | -587 Thousand AUD | 0.0% |
| 1999 Q3 | 251.78 Thousand AUD | 0.0% |
| 1999 FY | - AUD | 113.04% |
| 1999 Q1 | 251.78 Thousand AUD | 0.0% |
| 1999 Q2 | 251.78 Thousand AUD | 0.0% |
| 1999 Q4 | -587 Thousand AUD | -333.14% |
| 1998 FY | - AUD | 83.25% |
| 1998 Q4 | 251.78 Thousand AUD | 113.04% |
| 1998 Q3 | -1.93 Million AUD | 0.0% |
| 1998 Q2 | -1.93 Million AUD | 0.0% |
| 1998 Q1 | -1.93 Million AUD | 0.0% |
| 1997 Q2 | -11.52 Million AUD | 0.0% |
| 1997 Q1 | -11.52 Million AUD | 0.0% |
| 1997 Q3 | -11.52 Million AUD | 0.0% |
| 1997 FY | - AUD | -585.22% |
| 1997 Q4 | -1.93 Million AUD | 83.25% |
| 1996 Q2 | -1.68 Million AUD | 0.0% |
| 1996 Q4 | -11.52 Million AUD | -585.22% |
| 1996 Q1 | -1.68 Million AUD | 0.0% |
| 1996 Q3 | -1.68 Million AUD | 0.0% |
| 1996 FY | - AUD | -117.54% |
| 1995 Q4 | -1.68 Million AUD | -117.54% |
| 1995 FY | - AUD | 3629.35% |
| 1995 Q1 | 9.59 Million AUD | 0.0% |
| 1995 Q2 | 9.59 Million AUD | 0.0% |
| 1995 Q3 | 9.59 Million AUD | 0.0% |
| 1994 Q3 | -271.75 Thousand AUD | 0.0% |
| 1994 FY | - AUD | -146.69% |
| 1994 Q1 | -271.75 Thousand AUD | 0.0% |
| 1994 Q4 | 9.59 Million AUD | 3629.35% |
| 1994 Q2 | -271.75 Thousand AUD | 0.0% |
| 1993 FY | - AUD | 0.0% |
| 1993 Q2 | 582 Thousand AUD | 0.0% |
| 1993 Q4 | -271.75 Thousand AUD | -146.69% |
| 1993 Q1 | 582 Thousand AUD | 0.0% |
| 1993 Q3 | 582 Thousand AUD | 0.0% |
| 1992 Q4 | 582 Thousand AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AdAlta Limited | -5.3 Million AUD | 38.852% |
| Biome Australia Limited | -1.57 Million AUD | -105.45% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 92.854% |
| Biotron Limited | -5.04 Million AUD | 35.665% |
| Acrux Limited | -7.93 Million AUD | 59.116% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 83.433% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 76.705% |
| BTC Health Limited | 1.05 Million AUD | 407.263% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 71.305% |
| CSL Limited | 4.73 Billion AUD | 100.069% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 92.738% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 106.252% |
| Immutep Limited | -42.87 Million AUD | 92.437% |
| Memphasys Limited | -3.3 Million AUD | 1.971% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 101.627% |
| Noxopharm Limited | -5.94 Million AUD | 45.463% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 54.876% |
| Race Oncology Limited | -14.2 Million AUD | 77.171% |
| Starpharma Holdings Limited | -12.57 Million AUD | 74.219% |
| Tissue Repair Ltd | -5.77 Million AUD | 43.853% |
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 131.252% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -122.598% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -8.992% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 91.102% |
| Patrys Limited | -3.49 Million AUD | 7.149% |
| Orthocell Limited | -11.68 Million AUD | 72.241% |
| Imugene Limited | -147.97 Million AUD | 97.809% |
| PYC Therapeutics Limited | -38.11 Million AUD | 91.493% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | 58.89% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 67.413% |
| Arovella Therapeutics Limited | -8.83 Million AUD | 63.292% |
| Nanollose Limited | -1.14 Million AUD | -182.473% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -350.073% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -80.512% |
| Amplia Therapeutics Limited | -4.55 Million AUD | 28.886% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -15.059% |
| Nyrada Inc. | -4.59 Million AUD | 29.452% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 114.119% |
| Dimerix Limited | -24.95 Million AUD | 87.008% |
| PharmAust Limited | -9.45 Million AUD | 65.694% |
| Hexima Limited | -995.54 Thousand AUD | -225.703% |
| AnteoTech Limited | -11.57 Million AUD | 71.977% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 94.976% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 84.816% |
| Actinogen Medical Limited | -12.92 Million AUD | 74.905% |
| Immuron Limited | -6.19 Million AUD | 47.637% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -70.875% |